The AAK1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to eliminate AAK1 gene function in the human embryonic kidney HEK293T background. This product provides a heterogeneous pool of cells with targeted disruption of the AAK1 locus, enabling loss-of-function studies without clonal selection. By utilizing CRISPR/Cas9-mediated gene disruption, researchers can investigate AAK1-dependent processes in a widely employed, highly transfectable host cell line. The polyclonal format preserves genetic diversity while ensuring robust deactivation of the target kinase, making it suitable for population-level assays and high-throughput screening applications.
The parental HEK293T cell line is a derivative of HEK293 cells that stably expresses the SV40 large T antigen, permitting episomal replication of plasmids containing the SV40 origin of replication. These cells are extensively used for protein overexpression, transient transfection, and lentiviral production due to their human embryonic kidney origin and permissive growth characteristics. Their robust expression machinery and ease of manipulation make them an ideal platform for studying the molecular function of AAK1 in a controlled, non-neuronal cellular environment, while retaining key endocytic and signaling pathways.
AAK1 (Adaptor-Associated Kinase 1) is a serine/threonine kinase that critically regulates clathrin-mediated endocytosis by phosphorylating the ??2 subunit (AP2M1) of the AP-2 adaptor complex at Thr156. This phosphorylation event enhances cargo recognition and promotes clathrin coat assembly, driving internalization of cell-surface receptors and synaptic vesicle recycling. Beyond endocytosis, AAK1 phosphorylates the endocytic adaptor NUMB, which in turn inhibits Notch receptor activation. Thus, AAK1 acts as a negative regulator of Notch signaling by preventing NUMB-mediated suppression of Notch cleavage and transcriptional activity. Downstream effects involve modulation of Notch target genes such as HES1, linking AAK1 activity to broader transcriptional programs. Interacting partners include AP-2 complex subunits (AP2A2, AP2B1), clathrin heavy chain (CLTC), NUMB, NOTCH1, and presenilin-1 (PSEN1).
Disruption of AAK1 in HEK293T cells creates a powerful tool for dissecting AAK1-dependent endocytic and signaling mechanisms in a non-neuronal context that nevertheless expresses the core molecular machinery of clathrin-mediated endocytosis and Notch signaling. The knockout model is particularly valuable for pharmacological studies and drug target validation, as AAK1 is implicated in neuropathic pain, Alzheimer??s disease, and tauopathies. In HEK293T cells, the absence of AAK1 is expected to reduce AP2M1 Thr156 phosphorylation, impair transferrin uptake, and alter Notch-dependent transcriptional responses. This system facilitates high-throughput screening of AAK1 inhibitors and genetic interaction screens without the complexity of primary neuronal cultures.
Researchers can employ this knockout cell population in a variety of targeted assays. Western blotting for phospho-AP2M1 (Thr156) and AAK1 protein levels confirms knockout efficiency. Transferrin uptake assays measure clathrin-mediated endocytosis dynamics. NOTCH reporter luciferase assays or RT-qPCR for HES1 quantify Notch pathway activity. Co-immunoprecipitation experiments assess AAK1 interactions with AP-2 complex components. In-cell kinase activity assays and drug sensitivity testing with small-molecule AAK1 inhibitors further support preclinical development. For additional information, please contact Ascent Research.
